Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Inventiva $120 million underwritten offering
We advised the underwriters on the offering
Sumitomo Pharma ¥102.1 billion stock offering
We advised the joint lead managers and joint bookrunners on the offering
Roche acquisition of SAGA Diagnostics
We advised Roche on the transaction
CARsgen HK$470 million placement of shares and top-up subscription
We advised CARsgen on the placement and top-up subscription
Ingenovis Health comprehensive restructuring transactions
We advised Ingenovis Health in connection with the restructuring
Editas Medicine $125 million follow-on offering
We advised the joint book-running managers on the offering
Merck $6 billion notes offering
We advised the underwriters on the offering
Immix Biopharma $150 million stock offering
We advised the lead bookrunner and the underwriters on the offering
Oruka Therapeutics collaboration with Halozyme
We advised Oruka Therapeutics on the transaction
Purdue Pharma completes chapter 11 restructuring
We advised Purdue in connection with its nearly seven year-long chapter 11 restructuring